3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-12), Santhera Pharmaceuticals Holding AG's 3-1 Month Momentum % is -6.01%.
XSWX:SANN's 3-1 Month Momentum % is ranked better than 60.26% of 1389
companies
in the Biotechnology industry
Industry Median: -11.38
vs XSWX:SANN: -6.01
Santhera Pharmaceuticals Holding AG (XSWX:SANN) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Santhera Pharmaceuticals Holding AG 3-1 Month Momentum % Related Terms
XSWX:SANN vs VRTX, REGN, ALNY: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santhera Pharmaceuticals Holding AG 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Santhera Pharmaceuticals Holding AG's 3-1 Month Momentum % falls into.
Santhera Pharmaceuticals Holding AG (XSWX:SANN) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG (XSWX:SANN) has a 3-1 Month Momentum % of -6.01% as of Jul. 12, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. According to the industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #552 out of 1389 companies in the Biotechnology industry, placing it in the top 39.7%.
Is Santhera Pharmaceuticals Holding AG's 3-1 Month Momentum % too high?
Santhera Pharmaceuticals Holding AG's current 3-1 Month Momentum % is -6.01%. Based on the distribution chart, Santhera Pharmaceuticals Holding AG ranks #552 out of 1389 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #552 out of 1389 companies for 3-1 Month Momentum %. This puts Santhera Pharmaceuticals Holding AG in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. Santhera Pharmaceuticals Holding AG's current 3-1 Month Momentum % is -6.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG (XSWX:SANN) is currently considered Possible Value Trap. The stock's GF Value™ is CHF23.35, compared to a current price of CHF15.22 — trading 34.8% below its estimated fair value. The current 3-1 Month Momentum % is -6.01%. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (XSWX:SANN), the current 3-1 Month Momentum % is -6.01% as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santhera Pharmaceuticals Holding AG (XSWX:SANN) Overvalued in 2026?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued.
The current stock price of CHF15.22 is trading 34.8% below its estimated GF Value™ of CHF23.35.
GuruFocus considers Santhera Pharmaceuticals Holding AG to be Possible Value Trap.
Key valuation signals for XSWX:SANN:
3-1 Month Momentum %: -6.01%
GF Value™: CHF23.35 vs. price of CHF15.22 (34.8% below fair value)
No single metric tells the full story. See the XSWX:SANN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santhera Pharmaceuticals Holding AG Business Description
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score
Get the complete analysis for XSWX:SANN
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SANN has been successfully added to your 